DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Dalcetrapib
Dalcetrapib
Cholesteryl Ester-Transfer Protein Inhibitors Stimulate Aldosterone Biosynthesis in Adipocytes Through Nox-Dependent Processes S
Next-Generation Sequencing Transforms Today's Biology
PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
Study Design of Dal-Gene, a Pharmacogenetic Trial Targeting
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: the Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
Articles Article: Non-Statin Treatments for Managing LDL Cholesterol and Their Outcomes Download
Effects of the Cholesteryl Ester Transfer Protein Inhibitor Dalcetrapib in Patients with Recent Acute Coronary Syndrome
Stembook 2018.Pdf
Old and New in Lipid Lowering Therapy: Focus on The
Vascular Effects and Safety of Dalcetrapib in Patients with Or at Risk of Coronary Heart Disease: the Dal-VESSEL Randomized Clinical Trial
Study Protocol 1002-039 Amendment 1, 05 March 2017
The Dal-VESSEL Randomised Clinical Trial
Off-Target Vascular Effects of Cholesteryl Ester Transfer Protein
Product List
Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation Concordance with Clinical Outcomes
Dalcetrapib JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381
Top View
CT-16427 REPATHA REEVAL PIC AVIS3 CT16427.Pdf
Prevention of Murine Atherosclerosis with Bempedoic Acid
Functionality in Focus As HDL Hypothesis Awaits Confirmation
Novel Therapeutic Approaches to Elevate HDL-C and Modulate HDL Functionality
ACC 2019 – Anacetrapib Analysis Throws Doubt on Dalcor Play
Pharmacologic Therapies
(12) United States Patent (10) Patent No.: US 8,680,144 B2 Osterloh Et Al
Anacetrapib, a New CETP Inhibitor: the New Tool for the Management of Dyslipidemias?
Novel Therapies for HDL
Dalcor CVOT Moves Along; Seek Dalcetrapib CETP Win with Roche Diagnostic Test by Randy Osborne, Staff Writer
Safety and Tolerability of Dalcetrapib (RO4607381/ JTT-705): Results from a 48-Week Trial
Sara Rafi BW 9.Indd 20 a R A
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients with Coronary Heart Disease
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lipid Modification to Reduce Cardiovascular Risk
Nilemdo, INN-Bempedoic Acid
Hyperlipidemic Rabbit Models for Anti-Atherosclerotic Drug Development
WO 2019/030575 Al 14 February 2019 (14.02.2019) W !P O PCT
Cholesteryl Ester Transfer Protein Inhibitors for Dyslipidemia: Focus on Dalcetrapib
Cholesteryl Ester Transfer-Protein Modulator and Inhibitors and Their Potential for the Treatment of Cardiovascular Diseases